Connect with us

Hi, what are you looking for?

Tech & Science

Has the FDA Alzheimer’s drug approval been announced too early?

Experts say Alzheimer’s drug could prove a ‘major milestone’ as US regulators give green light.

City of centenarians points the way for China's ageing future
Decades of a one-child policy has built in a demographic challenge for China, with a low birth rate and the world's largest population of elderly to provide for - Copyright AFP WANG ZHAO
Decades of a one-child policy has built in a demographic challenge for China, with a low birth rate and the world's largest population of elderly to provide for - Copyright AFP WANG ZHAO

The U.S. Food and Drug Administration (FDA) has granted approved for a drug named aducanumab (manufactured by Biogen/Eisai). The drug, according to NPR, is designed to treat Alzheimer’s disease. It is a human monoclonal antibody.

What is important about the announcement is that this is the first drug that is clinically shown to slow the progression of Alzheimer’s disease. The evidence based approach has laid the foundations for the beginning of a completely generation of Alzheimer’s treatments.

The drug has been assessed across three trials. These studies show that the drug reduces amyloid in brain. The data assessment indicates there is a reasonable likelihood that the level of amyloid reduction will result in clinical benefit.

It is important to point out that aducanumab is not a cure. However, it is a very important advance for treatment. Furthermore, the therapy has not yet been tested on people with more advanced cases of dementia.

Over the past few decades, many researchers have argued that the accumulation of toxic beta-amyloid in the brain causes Alzheimer’s disease.

Amyloid plaques are aggregates of misfolded proteins. These abnormally configured proteins form in the spaces between nerve cells, first developing in the areas of the brain concerned with memory and other cognitive functions.

Amyloid is formed by the breakdown of larger protein molecules. Instead of being cleared (as in a normal brain) the proteins build up to abnormal levels, which causes a toxic effect. As the beta-amyloid proteins find each other, they aggregate or clump, forming plaques.

The intention of the medication is to provide people living with Alzheimer’s more time to live better.

Commenting on the announcement, Dr. Joanne Pike, who is the chief strategy officer for the Alzheimer’s Association, said: “This therapy will be of great interest to many, but it is not the only important element of Alzheimer’s treatment and care.”

With the FDA decision, this is a drug ruling known as ‘accelerated approval.’ This is common with drugs for cancer, but it has not been granted previously for a treatment for Alzheimer’s disease.

It is expected that the announcement will lead to an increase in investments in new treatments, as well as encouraging further innovation. However, not every advocate body is sold. Some organizations, such as The American Geriatrics Society, views the approval as “premature given the lack of sufficient evidence to support that aducanumab reduces progression of Alzheimer’s disease,”

Avatar photo
Written By

Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news. Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.

You may also like:

Entertainment

Musical artist ChewieCatt chatted about opening for Nick Carter of the Backstreet Boys on his "Who I Am" solo tour.

Social Media

Meanwhile, world, what are you doing about protecting your kids?

Entertainment

Veteran actor Maxwell Caulfield ("Grease 2") chatted about starring in the rom-com "The Merry Gentlemen" on Netflix.

Business

Hiring the right people is always important, but especially significant for newer businesses and startups.